Equities

Krystal Biotech Inc

Krystal Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)184.48
  • Today's Change1.74 / 0.95%
  • Shares traded365.60k
  • 1 Year change+52.29%
  • Beta0.8328
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform6
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Krystal Biotech Inc have a median target of 206.00, with a high estimate of 221.00 and a low estimate of 193.00. The median estimate represents a 11.67% increase from the last price of 184.48.
High19.8%221.00
Med11.7%206.00
Low4.6%193.00

Earnings history & estimates in USD

On Aug 05, 2024, Krystal Biotech Inc reported 2nd quarter 2024 earnings of 0.530 per share.
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate+495.81%
Krystal Biotech Inc reported annual 2023 earnings of 0.39 per share on Feb 26, 2024.
Average growth rate-66.98%
More ▼

Revenue history & estimates in USD

Krystal Biotech, Inc. had 2nd quarter 2024 revenues of 70.28m. This bettered the 65.34m consensus of the 8 analysts covering the company.
Average growth rate+151.75%
Krystal Biotech, Inc. had revenues for the full year 2023 of 50.70m.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.